Terug

Vivoryon Therapeutics AG

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 15 mrt 2016 - 08:21
  • Statutaire naam Vivoryon Therapeutics AG
  • Titel Probiodrug Reports Full Year 2015 Financial Results
  • Bericht Probiodrug reports full year 2015 financial results Phase 2a study of novel treatment for Alzheimer's disease initiated Phase 1 PQ912 data, a first in class Glutaminyl Cyclase (QC) inhibitor for the treatment of AD, prominently published Private Placement completed raising EUR 13.5 million HALLE/SAALE, Germany, 15 March 2016 Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced its financial results for the twelve-month period ending 31 December 2015 prepared in accordance with German GAAP ("HGB") and, on a voluntary basis, in accordance with IFRS as endorsed by the European Union. The Annual Reports are available on the company website (http://www.probiodrug.de/investors/reports-and-presentations/).

Gerelateerde downloads

201603150000000011_Probiodrug reports full year 2015 financial results.pdf

Datum laatste update: 24 juli 2019

Informatie delen

Delen via: deel